Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
03.09. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.09. | Oppenheimer initiates Pelthos Therapeutics stock with Outperform rating | 3 | Investing.com | ||
20.08. | Ligand Q1 2025: Umsatz steigt um 46 %, strategische Fusion zu Pelthos angekündigt | 1 | Investing.com Deutsch | ||
20.08. | Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced | 2 | Investing.com | ||
18.08. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
18.08. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update | 512 | GlobeNewswire (Europe) | Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI... ► Artikel lesen | |
13.08. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
25.07. | Pelthos Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
10.07. | Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI | 390 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first... ► Artikel lesen | |
10.07. | Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease | 1 | Benzinga.com | ||
10.07. | Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI | 257 | GlobeNewswire (Europe) | JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially... ► Artikel lesen | |
02.07. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.07. | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 436 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
02.07. | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 6 | Investing.com Deutsch | ||
02.07. | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
02.07. | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 211 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
27.06. | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha | ||
27.06. | Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement | 200 | GlobeNewswire (Europe) | FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment... ► Artikel lesen | |
14.05. | EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models | 2 | Benzinga.com | ||
13.05. | Channel Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,070 | +2,33 % | adidas, Evotec, Gerresheimer, Hensoldt, TeamViewer, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
VALNEVA | 4,920 | +7,61 % | Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ | ||
MAINZ BIOMED | 1,570 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt den Beginn der Vermarktung von ColoAlert® in der Schweiz bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Markteinführung
Mainz Biomed gibt den Beginn der Vermarktung von ColoAlert® in der Schweiz bekannt
23.09.2025... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 18,620 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
QIAGEN | 37,620 | +0,28 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 6,245 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
IMMUNOVANT | 16,060 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
NUVALENT | 84,84 | +4,24 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,655 | -0,69 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,915 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
DYNE THERAPEUTICS | 12,370 | 0,00 % | Dyne: Ministry Of Health In Japan Grants Orphan Drug Designation For DYNE-251 | ||
HARMONY BIOSCIENCES | 27,640 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
SUMMIT THERAPEUTICS | 21,155 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
RELAY THERAPEUTICS | 5,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 39,370 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |